ACW HY26 results - XanaMIA pivotal Alzheimers trial progress
Filed with ASX · · 5 pages · English
Actinogen Medical Limited on 6ix
Story so far
Earlier from Actinogen Medical
- Actinogen HY2025 financial report and Appendix 4D
- ACW receives further $1.9m FY2025 R&D rebate from ATO
- Actinogen receives positive Interim Analysis recommendation from its independent Data Monitoring Committee to continue the XanaMIA pivotal Alzheimer’s disease trial
- ACW secures funding beyond XanaMIA AD trial final results
- ACW December 2025 quarterly activity report & Appendix 4C
Later from Actinogen Medical
- ACW successfully completes $16.8m Placement and SPP
- ACW XanaMIA Alzheimers open label trial commences
- Actinogen commences open-label phase of XanaMIA Alzheimer’s trial and provides business update
- Correction-March2026 quarterly activity report & Appendix 4C
- Actinogen receives positive scientific advice from EMA
Follow Actinogen Medical into a list and get an email when it puts out news.
Follow Actinogen Medical